Contribution of Opiate Analgesics to the Development of Infections in Advanced Cancer Patients
| Autor: | Kai Ji, Wei Shuai Liu, Jian Lei Hao, Xian Jiang Cheng, Kun Wang, Bing Qing Guan, Yue Juan Shao |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Infections 03 medical and health sciences 0302 clinical medicine Risk Factors Neoplasms medicine Humans Pain Management Intensive care medicine Retrospective Studies Dose-Response Relationship Drug Morphine business.industry Palliative Care Cancer Immunosuppression Middle Aged medicine.disease Advanced cancer Analgesics Opioid Fentanyl Anesthesiology and Pain Medicine Logistic Models 030220 oncology & carcinogenesis Anesthesia Female Neurology (clinical) Opiate Cancer pain business 030217 neurology & neurosurgery Oxycodone Follow-Up Studies |
| Zdroj: | The Clinical journal of pain. 33(4) |
| ISSN: | 1536-5409 |
| Popis: | Literature is limited on the relationship between opiate analgesics and the development of infections in cancer patients. This study aimed to determine whether opiate analgesics contribute to the advancement of infections and how infection rates differ among the various opiates used for cancer management.From January 2013 to October 2014, we analyzed retrospectively 642 consecutive advanced cancer patients who received single types of opiates, including morphine, oxycodone, or fentanyl, or a combination of these drugs, continuously for14 days. Binominal logistic regression analysis was used to analyze the factors that may promote the development of infections.A total of 303 patients were included in the final analysis. Of these patients, 85, 41, and 68 patients received only morphine, oxycodone, and fentanyl, respectively. Altogether, 87 (28.7%) patients developed infections; 20 (23.5%), 10 (24.4%), and 14 (20.6%) patients developed infections in the groups that received only morphine, oxycodone, and fentanyl, respectively (P0.05). Logistic regression analysis found that the daily oral morphine equivalent (OME) is the an independent factor that influences the development of infection in the single-opiate group (odds ratio=1.002, P0.01). The risk for developing infection increased by 2% per 10 mg increase in the daily OME.Our clinical results did not display any difference among the single-opiate groups in the development of infections. However, the increase in daily OME may serve as a risk factor for the development of infections in advanced cancer patients using one opiate type for pain management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|